Annual report [Section 13 and 15(d), not S-K Item 405]

Consolidated Statements of Operations

v3.26.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Income Statement [Abstract]    
Revenues, net $ 11,421 $ 8,688
Cost of revenues 6,912 5,940
Gross profit 4,509 2,748
Operating expenses:    
Research and development 2 78
Selling, general and administrative 7,859 6,224
Total operating expenses 7,861 6,302
Loss from operations (3,352) (3,554)
Other income (expense)    
Change in fair value of warrant liability, net of warrant modification expense 118 28
Realized gain on investments in marketable securities 68
Interest expense, net (34) (81)
Change in fair value of contingent consideration (18)
Gain in spin-off of NexGelRx 162
Other expense (73) (4)
Other income 286 98
Total other income (expense), net 459 91
Loss before income taxes (2,893) (3,463)
Income tax expense
Net loss (2,893) (3,463)
Less: Loss attributable to non-controlling interest in joint venture (107) 182
Net loss attributable to NexGel stockholders $ (3,000) $ (3,281)
Net loss per common share - basic $ (0.38) $ (0.50)
Net loss per common share - diluted $ (0.38) $ (0.50)
Weighted average shares used in computing net loss per common share - basic 7,854,288 6,511,574
Weighted average shares used in computing net loss per common share - diluted 7,854,288 6,511,574